These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 22429766)

  • 21. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
    Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
    Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Understanding patient and physician perceptions of benign prostatic hyperplasia in Asia Pacific, Latin America and the Commonwealth of Independent States: the Prostate Research on Behaviour and Education (PROBE) II survey.
    Ertel P; Adalig B; Demircan I; Lartey B; Manyak MJ
    Int J Clin Pract; 2016 Oct; 70(10):870-880. PubMed ID: 27774780
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between Benign Prostatic Hyperplasia and Neutrophil-Lymphocyte Ratio, an Indicator of Inflammation and Metabolic Syndrome.
    Ozer K; Horsanali MO; Gorgel SN; Horsanali BO; Ozbek E
    Urol Int; 2017; 98(4):466-471. PubMed ID: 27464069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rural vs. urban disparities in association with lower urinary tract symptoms and benign prostatic hyperplasia in ageing men, NHANES 2001-2008.
    Egan KB; Suh M; Rosen RC; Burnett AL; Ni X; Wong DG; McVary KT
    Int J Clin Pract; 2015 Nov; 69(11):1316-25. PubMed ID: 26215544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between diabetes and clinical markers of benign prostatic hyperplasia among community-dwelling Black and White men.
    Sarma AV; Burke JP; Jacobson DJ; McGree ME; St Sauver J; Girman CJ; Lieber MM; Herman W; Macoska J; Montie JE; Jacobsen SJ
    Diabetes Care; 2008 Mar; 31(3):476-82. PubMed ID: 18071006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
    Shalekenov BU; Kuandykov YA; Shalekenov SB
    Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nocturia in Spanish patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Hernández C; Estivill E; Prieto M; Badía X
    Curr Med Res Opin; 2008 Apr; 24(4):1033-8. PubMed ID: 18302812
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvements in Self-reported Lower Urinary Tract Symptoms With Prostate Health Supplement.
    Eliaz I; Weil E; Wilk B
    Altern Ther Health Med; 2018 Sep; 24(5):26-32. PubMed ID: 29428929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
    MacDonald R; Tacklind JW; Rutks I; Wilt TJ
    BJU Int; 2012 Jun; 109(12):1756-61. PubMed ID: 22551330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of Benign Prostate Hyperplasia Based on Magnetic Resonance Imaging Are Correlated With Lower Urinary Tract Symptoms and Continence in Men Undergoing a Robot-assisted Radical Prostatectomy for Prostate Cancer.
    Grivas N; van der Roest R; Tillier C; Schouten D; van Muilekom E; Schoots I; van der Poel H; Heijmink S
    Urology; 2017 Sep; 107():196-201. PubMed ID: 28601562
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between Regular Aspirin Use and Circulating Markers of Inflammation: A Study within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    Lang Kuhs KA; Hildesheim A; Trabert B; Kemp TJ; Purdue MP; Wentzensen N; Katki HA; Pinto LA; Loftfield E; Safaeian M; Chaturvedi AK; Shiels MS
    Cancer Epidemiol Biomarkers Prev; 2015 May; 24(5):825-32. PubMed ID: 25713025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The changes of prostate specific antigen (PSA) after treatment with alpha 1-adrenergic receptor antagonists in men with 4.0-9.9 ng/ml PSA level--a study for comparison of benign prostatic hyperplasia/lower urinary tract symptom (BPH/LUTS) and prostate cancer].
    Hanai T; Matsumoto S; Shouji S; Usui Y; Tang XY; Kato Y; Iguchi M; Uemura H; Terachi T
    Hinyokika Kiyo; 2009 Apr; 55(4):187-91. PubMed ID: 19462822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
    Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
    Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A possible relationship between serum sex hormones and benign prostatic hyperplasia/lower urinary tract symptoms in men who underwent transurethral prostate resection.
    Wu Y; Pan H; Wang WM; Xu D; Zhang L; Gu ZQ; Bai Q; Qi J; Huang HF
    Asian J Androl; 2017; 19(2):230-233. PubMed ID: 26763548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. National trends in the use of PSA, urinalysis, and digital rectal exam for evaluation of lower urinary tract symptoms in men.
    Doolin J; Reese ZA; Mukamal KJ
    World J Urol; 2021 Mar; 39(3):855-860. PubMed ID: 32448971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.